171 related articles for article (PubMed ID: 21945642)
1. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
Broich K; Weiergräber M; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.
Hampel H; Broich K
J Nutr Health Aging; 2009 Apr; 13(4):373-5. PubMed ID: 19300885
[TBL] [Abstract][Full Text] [Related]
5. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
Truffinet P; Bordet R; Ménard J
Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
Broich K
Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121
[TBL] [Abstract][Full Text] [Related]
8. Need to improve clinical trials in rare neurodegenerative disorders.
Puopolo M; Pocchiari M
Ann Ist Super Sanita; 2011; 47(1):55-9. PubMed ID: 21430340
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
Disse B
Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
[TBL] [Abstract][Full Text] [Related]
10. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
11. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
12. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
13. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
14. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
Hampel H; Lista S; Khachaturian ZS
Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-based dissection of neurodegenerative diseases.
Olsson B; Zetterberg H; Hampel H; Blennow K
Prog Neurobiol; 2011 Dec; 95(4):520-34. PubMed ID: 21524681
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics in neurodegenerative disorders.
Zetterberg H; Rüetschi U; Portelius E; Brinkmalm G; Andreasson U; Blennow K; Brinkmalm A
Acta Neurol Scand; 2008 Jul; 118(1):1-11. PubMed ID: 18279484
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and surrogates in clinical studies.
Rigatto C; Barrett BJ
Methods Mol Biol; 2009; 473():137-54. PubMed ID: 19160736
[TBL] [Abstract][Full Text] [Related]
20. Prevention trials in Alzheimer's disease: an EU-US task force report.
Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
